NasdaqCM:VRDNBiotechs
Viridian Therapeutics (VRDN) Is Down 32.5% After Debated Phase 3 Elegrobart Data - What's Changed
Viridian Therapeutics recently reported positive topline results from its Phase 3 REVEAL-1 trial of elegrobart in active thyroid eye disease, showing significant improvements in eye bulging and double vision with subcutaneous dosing and a generally manageable safety profile.
Yet the data immediately sparked debate over how elegrobart stacks up against existing thyroid eye disease therapies, putting the focus on differentiation rather than simple success or failure of the trial.
Next, we’ll...